Lucid Biosystems is a US biotechnology company developing personalized cell therapies for solid tumors. Its platform identifies rare, natively active T-cells directly from patient tumors - selecting only immune cells that have already demonstrated correct tumor targeting.

Using single-cell functional assays, microcapillary technology, and RNA sequencing, Lucid derives patient-specific TCRs validated before use and engineers them into autologous cell therapies. This precision enables lower doses per patient, improved logistics, and reduced manufacturing time.

Lucid is advancing toward pre-IND readiness and seeking R&D partnerships. The platform builds on single-cell technology pioneered by RemedyBio, adapted specifically for cell therapy, driving substantial advantages in efficacy, safety, and cost.